Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-09-27Clinical Trial Update: An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer [Phase 1]
An investigational PET/CT imaging tracer, 124I-hJAA-F11, being evaluated for diagnosing lung cancer in a Phase 1 trial has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-09-20Clinical Trial Update: Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
The clinical trial evaluating immunogenicity and safety of pneumococcal vaccination in patients treated with immune checkpoint inhibitors fo…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial investigating allo-immunity to boost immune checkpoint inhibitor responses in Stage IV non-small cell lung …
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab [Phase 2]
A Phase 2 trial evaluating personalized duration of consolidation durvalumab guided by circulating tumor DNA in stage III non-small cell lun…
-
CLINICAL_TRIALS withdrawal · 2024-09-03Clinical Trial Update: SCION: SABR and Checkpoint Inhibition of NSCLC [Phase 2]
A Phase 2 trial (SCION) evaluating stereotactic ablative radiotherapy (SABR) with checkpoint inhibition for non-small cell lung cancer has b…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2024-08-22EMA Withdrawn: Tremelimumab AstraZeneca (tremelimumab) — AstraZeneca AB
EMA has withdrawn the marketing authorization for tremelimumab for non-small cell lung cancer.
-
CLINICAL_TRIALS withdrawal · 2024-08-09Clinical Trial Update: An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC [Phase 2]
Phase 2 exploratory trial exploring Adebelimumab with Famitinib and chemotherapy for non-small cell lung cancer was withdrawn. Sponsor: Jian…
-
EMA withdrawal · 2024-08-02EMA Withdrawn: Tizveni (tislelizumab) — BeiGene Ireland Ltd
The European Medicines Agency has withdrawn the marketing authorization for Tizveni (tislelizumab) by BeiGene Ireland Ltd for non-small cell…
-
EMA withdrawal · 2024-07-30EMA Withdrawn: Pemetrexed Krka (pemetrexed disodium) — KRKA d.d.
EMA has withdrawn the product Pemetrexed Krka (pemetrexed disodium) from the market.
-
CLINICAL_TRIALS withdrawal · 2024-07-09Clinical Trial Update: Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating a targeted RET therapy for RET-positive advanced non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-06-26Clinical Trial Update: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein [Phase 3]
A Phase 3 trial evaluating Telisotuzumab Vedotin in combination with Osimertinib or standard-of-care chemotherapy for EGFR-mutant, MET-overe…
-
CLINICAL_TRIALS withdrawal · 2024-06-20Clinical Trial Update: The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections [NA]
A clinical trial assessing whether combined general and regional anesthesia affects cancer recurrence after lung cancer surgery; the study h…
-
CLINICAL_TRIALS withdrawal · 2024-06-17Clinical Trial Update: Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations [Phase 2]
A Phase 2 trial evaluating capmatinib for CNS efficacy in non-small cell lung cancer with brain metastases and cfDNA-positive MET alteration…
-
CLINICAL_TRIALS withdrawal · 2024-06-12Clinical Trial Update: To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer [Phase 3]
Clinical trial NCT02974426, a Phase 3 study evaluating the timing of postoperative radiotherapy in stage IIIA (N2) non-small cell lung cance…
-
CLINICAL_TRIALS withdrawal · 2024-05-31Clinical Trial Update: Using Infrared Spectroscopy to Analyze Volatile Organic Compounds (VOCs) in the Breath of Patients With Lung Cancer
The clinical trial evaluating infrared spectroscopy of breath volatile organic compounds in lung cancer patients has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-05-29Clinical Trial Update: JDQ443 for KRAS G12C NSCLC Brain Metastases [Phase 2]
A Phase 2 trial of JDQ-443 for KRAS G12C-mutant non-small cell lung cancer with brain metastases has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy [Phase 2]
The Phase 2 trial investigating low-dose radiotherapy's effect on the tumor immune microenvironment in oligometastatic non-small cell lung c…
-
CLINICAL_TRIALS withdrawal · 2024-02-28Clinical Trial Update: Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen [Phase 4]
Phase 4 trial of pemetrexed plus apatinib maintenance in advanced non-squamous non-small cell lung cancer was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-07-24Clinical Trial Update: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. [Phase 3]
A Phase 3 trial evaluating ociperlimab with tislelizumab and chemotherapy in first-line locally advanced or metastatic non-small cell lung c…
-
CLINICAL_TRIALS withdrawal · 2023-07-03Clinical Trial Update: A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing ABP 215 to bevacizumab in Chinese patients with advanced non-squamous non-small cell lung cancer has been withdrawn.
-
EMA withdrawal · 2021-11-26EMA Withdrawn: Pemetrexed Lilly (pemetrexed) — Eli Lilly Netherlands
Pemetrexed Lilly (pemetrexed) was withdrawn from EMA evaluation across indications for non-small cell lung cancer and mesothelioma.
-
EMA withdrawal · 2021-07-29EMA Withdrawn: Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited) (pemetrexed ditromethamine) — Pfizer Europe MA EEIG
The EMA status indicates the pemetrexed product previously marketed by Hospira/Pfizer has been withdrawn. It was indicated for non-small cel…
-
CLINICAL_TRIALS withdrawal · 2020-10-19Clinical Trial Update: CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL [Phase 3]
A Phase 3 trial comparing CT-2103/Carboplatin vs Paclitaxel/Carboplatin for non-small cell lung cancer in women with estradiol > 25 pg/mL wa…
-
CLINICAL_TRIALS withdrawal · 2020-06-09Clinical Trial Update: INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) [Phase 3]
Phase 3 trial INCMGA00012 in combination with chemoradiation for stage III non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2019-11-22Clinical Trial Update: Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations [Phase 3]
Phase III trial comparing Nazartinib to Erlotinib/Gefitinib in first-line locally advanced/metastatic non-small cell lung cancer has been wi…